Moderna said on Wednesday that he had withdrawn a request requesting the approval of his candidate for the influenza vaccine and the combination covers after discussions with the Food and Drug Administration of the United States.
The company said that it would submit to its request later this year with vaccine efficiency data from a late stages trial of its experimental seasonal antigripping vaccine, which it plans to report this summer.
The decision comes one day after the American FDA said that it would require new clinical trials for the approval of the annual boosters of COVVI-19 for healthy people under the age of 65.
The company’s shares were beaten by the decrease in revenues cocvid as well as by the concerns of investors stimulated by the appointment of the vaccination skeptic Robert F Kennedy JR as secretary of the Ministry of Health and Social Services.
Actions dropped 1.4% more negotiation before marketing on Wednesday.
The FDA should make a decision on the COVVI-19 vaccine of the new generation of Moderna, which is a component of the shot combined with flu, at the end of the month. Moderna previously declared that he does not expect a delay in this decision.
Moderna in early May postponed time for the likely approval of its combined vaccine – intended to protect adults aged 50 and over against COVID -19 and the flu – until 2026.
The company has implemented income from new mRNA fire to compensate for the drop in sales of its coche vaccine and less than expected adoption of its vaccine against the respiratory syncytial virus, which sent its shares to almost 60% last year.
